Year in Review Financial Positioned to return to sustainable growth. Research and development Delivering CSL’s portfolio. People Enable CSL’s people to deliver the Company’s future. Underlying NPATA attributable to equity holders of US$3.1 billion for the year ended 30 June 2026, down 2% on a constant currency basis when compared to the prior comparable period. US$11,387m CSL Behring revenue US$2,031m CSL Seqirus revenue US$2,379m CSL Vifor revenue Cash flow from operations was $3,512 million. Maintained our total dividend payments for FY2026 at US$2.92 per share. Returned capital to shareholders through the completion of the A$1 billion share buy-back program. Strategic collaboration with VarmX CSL entered into a strategic collaboration with privately held Dutch biotech company VarmX BV, to support the company’s development of VMX-C001. VMX-C001 is a novel treatment to help restore blood coagulation in patients requiring urgent surgery or procedures while taking Factor Xa inhibitors. Under the terms of the strategic collaboration agreement, CSL will fund VarmX’s global Phase 3 trial evaluating VMX-C001 in patients taking Factor Xa inhibitors who require urgent surgery. CSL, which has an option to acquire VarmX, will also fund and support VarmX in late-stage product development, manufacturing and pre-launch commercial and medical affairs activities. ANDEMBRY® paediatric Positive Phase 3 results for garadacimab (ANDEMBRY®) in children aged 2–11 with hereditary angioedema (HAE) showed strong safety and disease control, supporting planned regulatory filings to expand access to younger patients. + R EAD MORE ABOUT CSL’S R&D PIPELINE AT CSL.COM/RESEARCH-ANDDEVELOPMENT/PRODUCT-PIPELINE 21,891 (79%) respondents to 2026 Employee Engagement Survey. 67.2%* 2026 Engagement Index. Our Global Leadership Team is driving improvements in employee engagement through targeted objectives and action plans, while senior leaders are conducting focus groups on two priorities: faster decision-making and clearer strategic direction. 75.5% Leadership Index Introduced in FY2026, the Leadership Index averages five manager-employee relationship indicators. Our inaugural global score shows employees’ confidence in their leaders across CSL. 375 CSL’s Leadership Cohort program invests in 375 leaders in our most critical roles, building a future-ready leadership pipeline aligned to support long-term growth 81,958 global recognition moments shared in Celebrate the Promise Program** + R EAD MORE IN TALENT AND CULTURE ON PAGE 32 * Limited assurance by Deloitte. ** As at 30 June 2026. 6 Performance
RkJQdWJsaXNoZXIy MjE2NDg3